Does Physiological Uptake Mean Cancer

Reading PET Scans: The Physiological Uptake Problem

When a patient comes back from a PET/CT showing focal uptake, the first instinct is to mark it as suspicious. That instinct is wrong about half the time. Physiological uptake is the normal biodistribution of FDG across tissues, and it is one of the most common sources of false-positive readings in nuclear medicine. Understanding the difference between normal tracer accumulation and actual pathology is not something you pick up from a textbook overnight. It takes seeing enough patterns to stop second-guessing yourself. FDG is a glucose analog. It enters cells through GLUT transporters and gets phosphorylated by hexokinase. Once that happens, it cannot proceed through glycolysis, so it accumulates. Tissues with high metabolic demand show up bright. Brain, myocardium, kidneys, bladder — these are obvious. The harder cases are the ones that sit in the gray zone, like the upper pole of a kidney that occasionally lights up or a patch of brown fat that appears when a patient is cold. I have spent more hours arguing over whether a retroperitoneal focus was lymphoma or just excreted tracer than I care to admit.

Does Physiological Uptake Mean Cancer

No. Physiological uptake means exactly what the name says — it is the expected, non-pathological accumulation of radiotracer in normal tissues. The confusion arises because the imaging appearance can overlap with malignancy. A symmetric, tubular pattern of bowel uptake looks nothing like cancer. Asymmetric, focal, intense uptake in a lymph node station raises a different set of concerns. The key discriminators are symmetry, intensity relative to background, anatomical correlation on the CT component, and clinical context. Brown adipose tissue is a classic pitfall. It shows up in the supraclavicular region, along the paravertebral chain, and around the mediastinum. On CT it is simply fat-density tissue — no mass effect, no lymphadenopathy. If you are reading a scan without the CT fusion, you can easily mistake it for metastatic disease. The workaround is straightforward: keep the temperature low before scanning, use a warm blanket during transport, and check for that characteristic symmetric pattern. I had a case once where a woman's paratracheal uptake was called suspicious on the initial read. She had no known primary. The fused images showed symmetric uptake in the interpolar region of the kidneys with no corresponding soft tissue mass. It was physiological. The initial concern was resolved within ten minutes of looking at the right combination of images. Myocardial uptake is another area where beginners trip. The heart can take up FDG variably depending on the patient's preparation. If a patient has not been fasting or placed on a high-fat, low-carbohydrate diet prior to the scan, the heart will compete with potential lesions for the tracer. A diffuse patchy pattern in the left ventricle is normal physiology. Focal, asymmetric, intense uptake in the myocardium could represent a granuloma, a tumor, or infection — but that requires SPECT/CT correlation or additional imaging, not just a standalone PET read. I usually flag borderline cardiac uptake and recommend either a follow-up scan with proper dietary prep or an MRI if the clinical question is urgent.

Salivary gland uptake is benign when it is bilateral and symmetric. Iodide analogs and certain medications can cause unilateral predominance, which sometimes gets misread as a parotid mass. The CT component almost always clarifies this, but if you are working from PET alone, you need to be careful. Urinary tract uptake is inevitable with FDG — it is excreted renally. Dehydration concentrates the tracer in the collecting system and can produce intense focal spots that mimic bladder or ureteral tumors. Hydration and diuresis protocols reduce this significantly. I make sure my patients are well-hydrated and void before imaging whenever possible. A standard 500ml water load thirty minutes before injection can cut down on urinary artifact without affecting image quality elsewhere. The real problem with physiological uptake is not identifying the obvious cases. It is recognizing the variants that sit just outside the norm. Lymphoid tissue in the Waldeyer ring and along the ileocecal valve is normal. When it is prominent — which happens after viral illnesses or in young patients — it can look alarming. I once followed a case for six months where diffuse small-bowel uptake was attributed to early lymphomatous infiltration. Repeat scan after antibiotics showed complete resolution. It was infectious colitis, not cancer. The initial concern was legitimate, but the conclusion was premature. There is no single threshold that separates physiological from pathological SUV values. An SUV of 2.5 in one location might be normal. The same value in another location could be malignant. Context determines everything. I use a combination of criteria: symmetry, intensity relative to liver baseline, morphological correlation on CT, temporal evolution on follow-up scans, and clinical probability. When all four align, the call is straightforward. When they diverge, the call becomes harder and often requires a multidisciplinary discussion rather than a definitive statement from a single modality.

The limitations of PET for this purpose are real. Resolution is around 4 to 5 millimeters for modern scanners. Lesions smaller than that will not localize properly regardless of their metabolic activity. Partial volume effects cause small lesions to appear less intense than they actually are, which can produce false negatives. Conversely, inflammation from recent biopsy, radiation, or infection can produce intense uptake that mimics malignancy. I have seen post-radiation pneumonitis light up so brightly on a follow-up scan that it was indistinguishable from recurrence without knowing the treatment history. Clinical history is not optional. It is the most important piece of data on the report. If you are dealing with persistent uncertainty, the practical next steps are repeat imaging in three to six months, cross-reference with contrast-enhanced CT or MRI, or in some cases a biopsy. PET is a functional modality. It tells you where metabolism is high, not what is causing it. The structural information from CT or the tissue specificity from biopsy closes the gap. Neither modality is sufficient alone when the presentation is ambiguous.